Cargando…
Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer
With the recent comprehensive mapping of cancer genomes, there is now a need for functional approaches to edit the aberrant epigenetic state of key cancer drivers to reprogram the epi-pathology of the disease. In this study we utilized a programmable DNA-binding methyltransferase to induce targeted...
Autores principales: | Stolzenburg, S, Beltran, A S, Swift-Scanlan, T, Rivenbark, A G, Rashwan, R, Blancafort, P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4633433/ https://www.ncbi.nlm.nih.gov/pubmed/25684141 http://dx.doi.org/10.1038/onc.2014.470 |
Ejemplares similares
-
Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer
por: Stolzenburg, Sabine, et al.
Publicado: (2012) -
Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function
por: Beltran, A S, et al.
Publicado: (2014) -
DNA methylation prevents CTCF-mediated silencing of the oncogene BCL6 in B cell lymphomas
por: Lai, Anne Y., et al.
Publicado: (2010) -
De novo design of stable proteins that efficaciously inhibit oncogenic G proteins
por: Cummins, Matthew C., et al.
Publicado: (2023) -
De novo DNA methylation promoted by G9a prevents reprogramming of embryonically silenced genes
por: Epsztejn-Litman, Silvina, et al.
Publicado: (2008)